摘要
目的评价并比较氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效及安全性。方法将2002年8月至2006年2月于中国医科大学附属第一医院接受化疗的恶性淋巴瘤患者66例,按照治疗方案分成氟达拉滨联合米托蒽醌组(简称“氟达拉滨组”)和CHOP组,对2组的疗效及不良反应进行分析和比较。结果氟达拉滨组总有效率为81·5%,而CHOP组为48·7%;对晚期淋巴瘤、B细胞淋巴瘤及伴有血清乳酸脱氢酶(LDH)升高的淋巴瘤患者氟达拉滨组总有效率均高于CHOP组,组间比较差异均有显著性意义(P均<0·05)。氟达拉滨组血液学不良反应与CHOP组类似,而非血液学不良反应较少。结论以氟达拉滨为基础的联合化疗方案治疗初治恶性淋巴瘤以及难治、复发、晚期的恶性淋巴瘤的疗效、安全性及患者的耐受性均优于CHOP方案。
Objective To investigate the efficacy and safety of fludarabine plus mitoxantrone combination chemotherapy for malignant lymphoma compared with CHOP regimen. Methods Sixty-six patients with malignant lymphoma were divided into fludarabine group and CHOP group. The efficacy and toxicities of these two regimens were analyzed and compared between the two groups. Results The overall response（OR）was 81.5% in fludarabine group,while was 48. 7% in CHOP ;for the patients in late-stage, with B cell lymphoma, with T cell lymphoma and with high serum LDH level, the OR in fludarabine group was higher than in CHOP group obstructively,being 62.5% and 35.7%. Conclusion Fludarabine combination chemotherapy, as a first line regimen in treating first-treated lymphoma, recrudescent lymphoma, intractable lymphoma and lymphoma in late stage, possesses higher efficacy, safety and tolerance than CHOP regimen.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2007年第11期851-852,共2页
Chinese Journal of Practical Internal Medicine
